Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Teva offers EU concessions over Allergan generics deal – EU

Teva Pharmaceutical Industries Ltd (TEVA.TA) has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan’s (AGN.N) generics unit which will cement its position as the world’s largest generics drugmaker.   “Commitments have been submitted and the new legal deadline is set on 10 March,” European Commission spokesman Ricardo Cardoso said […]

Read More »

Novartis wins FDA breakthrough therapy for AML treatment

Novartis received breakthrough therapy designation from the U.S. Food and Drug Administration for an investigational treatment for newly-diagnosed FLT3-mutated acute myeloid leukemia, the Swiss drugmaker said on Friday. Patients who received PKC412, also called midostaurin, combined with standard induction and consolidation chemotherapy experienced what Novartis called “a significant improvement in overall survival”. With the announcement, […]

Read More »

Ogilvy CommonHealth Worldwide launches Ogilvy CommonHealth NANO

Agency created to address the unique needs of smaller to midsize healthcare clients PARSIPPANY, N.J., February 18- Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY,, today announced the launch of a new agency—Ogilvy CommonHealth NANO—created to serve the distinct brand needs of […]

Read More »

Onconova Cuts 17% of Staff and CEO Takes $136K Pay Cut

February 18, 2016By Mark Terry, Breaking News Staff   Newton, Pa.-based Onconova Therapeutics (ONTX), in an effort to cut costs and hold on to its cash, indicated it is cutting 17 percent of its workforce, including the company’s chief financial officer and president of research and development. The company’s chief executive officer, Ramesh Kumar, […]

Read More »

Former GSW creative officer to lead Fingerpaint’s ideation group

Bruce Rooke, one of the best-known creative minds in healthcare advertising and former global creative officer at GSW, has taken up a brand-new position at Fingerpaint, the Saratoga Springs, N.Y., shop started by former Palio founder Ed Mitzen. Rooke, who will operate from his home in Columbus, Ohio, as well as the agency’s Saratoga Springs […]

Read More »

World Bank offers $150 million financing to countries affected by Zika

The World Bank said on Thursday it is making $150 million in financing immediately available to help combat the Zika virus outbreak in affected Latin American and Caribbean countries.   The multilateral lender said in a statement that it stands ready to increase its support if needed, and the initial amount is based on current […]

Read More »

Zafgen obesity drug succeeds in mid-stage trial, shares rise

Zafgen Inc’s controversial obesity drug reduced the weight of overweight diabetic patients, the second trial success in as many months for the drug on which all tests have been halted since December after two patients died. The company said on Thursday patients given 1.8 mg and 1.2 mg doses of beloranib lost 12.7 and 13.5 […]

Read More »

303 Fetal Deaths May be Linked to Bayer HealthCare’s Essure

U.S. Rep. Mike Fitzpatrick fired off allegations that Bayer HealthCare’s contraceptive device Essure is directly related to 303 fetal deaths.

Read More »

Pliant Launches in the Bay Area With $45 Million

February 18, 2016By Mark Terry, Breaking News Staff   Redwood City, Calif.-based Third Rock Ventures, LLC launched a new biotech company, Pliant Therapeutics, Inc., today with $45 million in Series A financing. The company’s focus will be on developing drugs to treat various fibrotic disorders. Pliant’s science is based on the work of Dean […]

Read More »

UK cost agency queries value of $700,000-a-year Alexion drug

An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain’s healthcare cost watchdog said. Kanuma is designed for treating lysosomal acid lipase (LAL) deficiency, a rare inherited genetic disease in which fats build […]

Read More »

Renaissance RX Faces New Employee Lawsuit, Fraud Allegations

February 18, 2016 By Alex Keown, Breaking News Staff   NEW ORLEANS — The once promising Renaissance RX, a personalized medicine firm specializing in genetic testing, is facing allegations of fraud in an employee lawsuit, the Advocate of Louisiana reported Wednesday. Alison Diboll, who relocated to New Orleans from California to take a marketing […]

Read More »

Medical Advertising Hall of Fame Honors Sudler Future Famers

New York, February 18, 2016 – The Sudler & Hennessey network, an agency leader in healthcare communications, proudly announces that Connor Delaney, Chelsea Higgins, and Cassidy Crook were honored with the Medical Advertising Hall of Fame Future Famers award, presented at the recent 2016 MAHF Awards ceremony held in NYC. Over the past decade, the […]

Read More »

IntraMed Honored With Medical Advertising Hall of Fame’s Digital Pioneer Award

New York, February 17, 2015––IntraMed Educational Group, Sudler & Hennessey’s flagship medical education division, was honored with the Digital Pioneer Award for their 1996 project The Physician’s Internet Tutorial. The award was presented at the recent 2016 Medical Advertising Hall of Fame Awards ceremony held in NYC. “It’s hard to remember a time when we […]

Read More »

Sudler Honored With Medical Advertising Hall of Fame Heritage Award

New York, February 16, 2015––Sudler New York has been named a recipient of the 2016 Medical Advertising Hall of Fame Heritage Award. The Heritage Award, established to preserve the history of healthcare advertising by acknowledging those whose contributions have made a positive difference, was given to Sudler for what is referred to as the “Mona […]

Read More »

Corvidia Therapeutics Raises $26 Million in Series A Financing

Company Announces Licensing Agreement with AstraZeneca   BOSTON, Feb. 17, 2016 /PRNewswire/ — Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.     Concurrent with the financing, Corvidia […]

Read More »

Fingerpaint Appoints Industry Veteran Bruce Rooke To Create “Perpetual Ideation Machine”

Fingerpaint has announced the hire of advertising veteran Bruce Rooke to lead an ideation/innovation group that will expand the full-service agency to challenge and answer the needs of an ever-changing communications landscape.

Read More »

McCann Health Appoints Tammy Fischer Chief Growth Officer for North America

New York (February 17, 2016) — McCann Health today announced that Tammy Fischer has been appointed to the new role of Executive Vice President, Chief Growth Officer, for McCann Health North America. Ms. Fischer joins McCann Health with over two decades of healthcare expertise, including top positions at other healthcare agencies. She was President of GSW […]

Read More »

WHO seeks $56 million for plan to combat Zika virus

The World Health Organization (WHO) said on Wednesday that $56 million would be needed until June to fund a strategy to combat the Zika virus which has spread to 39 countries and has been linked to birth defects in Brazil.   The funds sought, including $25 million for the WHO, would be used to fast-track […]

Read More »

Regulus hep C combination drug effective in mid-stage study

Regulus Therapeutics Inc said interim data showed that patients tested with its hepatitis C drug combination treatment displayed sustained viral response in an ongoing mid-stage study, sending its shares up 43 percent in premarket trading. The company’s shares were up at $9.25 in heavy premarket trading on Wednesday. Regulus said it tested its injection, RG-101, […]

Read More »

FDA gives ocrelizumab breakthrough designation for PPMS: Roche

The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUS) for treating people with primary progressive multiple sclerosis (PPMS), Swiss drugmaker Roche said on Wednesday.   There are no approved treatments now for PPMS, a debilitating form of the disease marked by steadily worsening symptoms. “Roche plans to pursue marketing authorization […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom